Answers are grounded in this paper and cite their sources.
Adjuvant chemotherapy (AC) following pancreatic carcinoma (PC) resection improves overall survival (OS). A systematic review identified 10 phase-2/3 studies investigating AC in 3644 patients looking at the influence of nodal and resection status. AC significantly improved disease free survival, OS and 5-year odds of death risk. There was greater survival benefit in patients PS 0 and with body/tail tumors. There was a nonsignificant effect in N ⁻ /N ⁺ patients on OS and no difference between R0/R1 patients.
No takes yet. Share an insight, caveat, or question.
Flaum et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: